Although the use of intensive insulin therapy since the DCCT trial has greatly reduced the incidence of micro- and macroangiopathic complications of diabetes [11], in these patients, a reduced life expectancy and an increased prevalence of micro- and macroangiopathic complications remain even when glycemic compensation (estimated with Hba1c) appears optimal [8,12,13]. The gene discussed is INS; the disease is diabetes mellitus.